Rachel L. Stewart

Rachel L. Stewart

Auto-generated profile, based on publicly available information

Rachel L. Stewart

University of Kentucky

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
GXGaofeng Xiong
Gaofeng Xiong
RSRachel L. Stewart
Rachel L. Stewart
JCJie Chen
Jie Chen
TGTianyan Gao
Tianyan Gao
TSTimothy L. Scott
Timothy L. Scott
RXRen Xu
Ren Xu
Collagen prolyl 4-hydroxylase (P4H) expression and collagen hydroxylation in cancer cells are necessary for breast cancer progression. Here, we show that P4H alpha 1 subunit (P4HA1) protein expression is induced in triple-negative breast cancer (TNBC) and HER2 positive breast cancer. By modulating alpha ketoglutarate (α-KG) and succinate levels P4HA1 expression reduces proline hydroxylation on hypoxia-inducible factor (HIF) 1α, enhancing its stability in cancer cells. Activation of the P4HA/HIF-1 axis enhances cancer cell stemness, accompanied by decreased oxidative phosphorylation and reactive oxygen species (ROS) levels. Inhibition of P4HA1 sensitizes TNBC to the chemotherapeutic agent docetaxel and doxorubicin in xenografts and patient-derived models. We also show that increased P4HA1 expression correlates with short relapse-free survival in TNBC patients who received chemotherapy. These results suggest that P4HA1 promotes chemoresistance by modulating HIF-1-dependent cancer cell stemness. Targeting collagen P4H is a promising strategy to inhibit tumor progression and sensitize TNBC to chemotherapeutic agents.

1 September 2015 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
RSRachel L Stewart
Rachel L Stewart
Kathleen L. O'ConnorKathleen L. O'Connor
Kathleen L. O'Connor
Integrin α6β4 is a cellular adhesion molecule that binds to laminins in the extracellular matrix and nucleates the formation of hemidesmosomes. During carcinoma progression, integrin α6β4 is released from hemidesmosomes, where it can then signal to facilitate multiple aspects of tumor progression including sustaining proliferative signaling, tumor invasion and metastasis, evasion of apoptosis, and stimulation of angiogenesis. The integrin achieves these ends by cooperating with growth factor receptors including EGFR, ErbB-2, and c-Met to amplify downstream pathways such as PI3K, AKT, MAPK, and the Rho family small GTPases. Furthermore, it dramatically alters the transcriptome toward a more invasive phenotype by controlling promoter DNA demethylation of invasion and metastasis-associated proteins, such as S100A4 and autotaxin, and upregulates and activates key tumor-promoting transcription factors such as the NFATs and NF-κB. Expression of integrin α6β4 has been studied in many human malignancies where its overexpression is associated with aggressive behavior and a poor prognosis. This review provides an assessment of integrin α6β4 expression patterns and their prognostic significance in human malignancies, and describes key signaling functions of integrin α6β4 that contribute to tumor progression.

5 December 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJingyi Liu
Jingyi Liu
ZDZhibing Duan
Zhibing Duan
WGWeijie Guo
Weijie Guo
LZLei Zeng
Lei Zeng
YWYadi Wu
Yadi Wu
JSJian Shi
Jian Shi
BRD4 assembles transcriptional machinery at gene super-enhancer regions and governs the expression of genes that are critical for cancer progression. However, it remains unclear whether BRD4-mediated gene transcription is required for tumor cells to develop drug resistance. Our data show that prolonged treatment of luminal breast cancer cells with AKT inhibitors induces FOXO3a dephosphorylation, nuclear translocation, and disrupts its association with SirT6, eventually leading to FOXO3a acetylation as well as BRD4 recognition. Acetylated FOXO3a recognizes the BD2 domain of BRD4, recruits the BRD4/RNAPII complex to the CDK6 gene promoter, and induces its transcription. Pharmacological inhibition of either BRD4/FOXO3a association or CDK6 significantly overcomes the resistance of luminal breast cancer cells to AKT inhibitors in vitro and in vivo. Our study reports the involvement of BRD4/FOXO3a/CDK6 axis in AKTi resistance and provides potential therapeutic strategies for treating resistant breast cancer.

15 January 2018 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
MBMarilyn Bui
Marilyn Bui
MRMichael W. Riben
Michael W. Riben
KAKimberly H. Allison
Kimberly H. Allison
ECElizabeth Chlipala
Elizabeth Chlipala
CCCarol Colasacco
Carol Colasacco
MHM. Elizabeth Hammond
M. Elizabeth Hammond
Context.—: Advancements in genomic, computing, and imaging technology have spurred new opportunities to use quantitative image analysis (QIA) for diagnostic testing. Objective.—: To develop evidence-based recommendations to improve accuracy, precision, and reproducibility in the interpretation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) for breast cancer where QIA is used. Design.—: The College of American Pathologists (CAP) convened a panel of pathologists, histotechnologists, and computer scientists with expertise in image analysis, immunohistochemistry, quality management, and breast pathology to develop recommendations for QIA of HER2 IHC in breast cancer. A systematic review of the literature was conducted to address 5 key questions. Final recommendations were derived from strength of evidence, open comment feedback, expert panel consensus, and advisory panel review. Results.—: Eleven recommendations were drafted: 7 based on CAP laboratory accreditation requirements and 4 based on expert consensus opinions. A 3-week open comment period received 180 comments from more than 150 participants. Conclusions.—: To improve accurate, precise, and reproducible interpretation of HER2 IHC results for breast cancer, QIA and procedures must be validated before implementation, followed by regular maintenance and ongoing evaluation of quality control and quality assurance. HER2 QIA performance, interpretation, and reporting should be supervised by pathologists with expertise in QIA.

1 August 2016 in Human Pathology
Verified
Journal Article
Closed access
RSRachel L. Stewart
Rachel L. Stewart
DWDava West
Dava West
CWChi Wang
Chi Wang
HWHeidi L. Weiss
Heidi L. Weiss
TGTamas Gal
Tamas Gal
Kathleen L. O'ConnorKathleen L. O'Connor
Kathleen L. O'Connor

25 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
RSRachel L. Stewart
Rachel L. Stewart
BCBrittany L. Carpenter
Brittany L. Carpenter
DWDava S. West
Dava S. West
TKTeresa Knifley
Teresa Knifley
LLLili Liu
Lili Liu
MCMin Chen
Min Chen
S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide